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Abstract
Background: Acute rejection (AR) episodes in renal transplant recipients are suspected when plasma creatinine is
elevated and other potential causes out ruled. Graft biopsies are however needed for definite diagnosis. Non-
invasive AR-biomarkers is an unmet clinical need. The urinary proteome is an interesting source in the search for
such a biomarker in this population.
Methods: In this proof of principle study, serial urine samples in the early post transplant phase from 6 patients
with biopsy verified acute rejections and 6 age-matched controls without clinical signs of rejection were analyzed
by shotgun proteomics.
Results: Eleven proteins fulfilled predefined criteria for regulation in association with AR. They presented detectable
regulation already several days before clinical suspicion of AR (increased plasma creatinine). The regulated proteins
could be grouped by their biological function; proteins related to growth and proteins related to immune
response. Growth-related proteins (IGFBP7, Vasorin, EGF and Galectin-3-binding protein) were significantly up-
regulated in association with AR (P= 0.03) while proteins related to immune response (MASP2, C3, CD59,
Ceruloplasmin, PiGR and CD74) tended to be up-regulated (P= 0.13).
Conclusion: The use of shotgun proteomics provides a robust and sensitive method for identification of potentially
predictive urinary biomarkers of AR. Further validation of the current findings is needed to establish their potential
clinical role with regards to clinical AR diagnosis.
Trial registration: ClinicalTrials.gov number NCT00139009
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Background
Patients whom experience an acute rejection (AR) after
renal transplantation have an increased risk of develop-
ing chronic allograft nephropathy and reduced long-
term graft survival [1-5]. In a clinical setting an AR is
typically suspected upon an increase in plasma creatin-
ine that cannot be explained by other plausible causes,
and verified by histological examination of core biopsies
from the graft [6]. This method is however flawed by
both late and unspecific onset of plasma creatinine
increase and sampling heterogeneity and poor correl-
ation with treatment response and prognosis for biopsy
results.
Even though renal biopsying per se is considered a rela-
tively safe procedure when appropriate clinical precau-
tions are taken, it is a time-consuming invasive procedure
which is cumbersome for the patients and has potential
side effects [7]. In the general follow-up of transplanted
patients a non-invasive method with high sensitivity and
specificity for diagnosing AR is desirable. Of the many dif-
ferent methods and matrices plausible for such monitor-
ing, the urinary proteome is maybe one of the most
appropriate. It can be accessed non-invasively and the
proteome reflects the last step in molecular regulation of
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immune responses. About 30% of the urinary proteome
comes from plasma while the rest is locally produced in
the kidney, increasing the possibility of reflecting kidney
specific processes [8,9]. This is likely an advantage when
monitoring graft function and events in kidney transplant-
ation. Several attempts have been made to identify pos-
sible urinary biomarkers for AR [10-24], but none are
currently used clinically [25,26]. Most of the studies done
are hypothesis based and only focus on a few specific tar-
get proteins. The development in the field of mass spec-
trometry has, however, made screening analysis of the full
proteome technically possible. Recently, Sigdel et al. used
shotgun proteomics to identify proteins in pooled urine
samples from pediatric kidney transplants with acute re-
jection [20].
We performed a small prospective proof of principle
study in order to show the applicability of using shotgun
proteomics in serial samples from distinct individuals in
the search for urinary proteins that are regulated in as-
sociation with AR episodes. In shotgun proteomics pro-
teins are enzymatically digested into peptides, which are
separated by liquid chromatography, coupled to a mass
spectrometer, in this case a state of the art LTQ-Orbi-
trap. This enables analysis of the whole proteome in one
experiment utilizing the increased sensitivity offered by
MS-detection of peptides instead of intact proteins. The
very complex peptide mixture resulting from tryptic di-
gestion of proteins requires more molecular information
for unambiguous identification, which is achieved by the
use of tandem mass spectrometry. After the first mass
scan energy is added to the peptides, resulting in frag-
mentation and cleavage into amino acids which can be
detected in the next mass scan allowing peptide sequen-
cing and subsequent protein identification by database
searches. In order to quantify protein levels in this
method, samples were labeled with the stable 18O iso-
tope and compared with respective baseline sample. The
typical time-span of one single analysis is approximately
4–5 days, making this approach unsuitable for routine
analysis. With this experimental setup the respective
samples are mixed early in the process, acting as each
other’s controls, which eliminates many of the factors
contributing to experimental variability.
Patients and methods
Study design and samples
We used urine samples from 6 renal transplant patients
with BPAR during the first post transplant months and
from 6 renal transplant patients with stable graft func-
tion in the same period, matched for age, immunosup-
pression and time after transplantation. All urine
samples were collected prospectively as part of an at that
time ongoing study of twenty renal transplant recipients
at Oslo University Hospital, Rikshospitalet [27]. On
average urine samples were available from 4.7 ± 2.7 days
after transplantation and the patients were followed for
8–10 weeks. All patients received induction with intra-
venous basiliximab on day 0 and 4, cyclosporine A
(CsA), mycophenolate mofetil 1 g BID and steroids.
Urinary samples were collected three times weekly the
first two weeks, twice weekly the next four weeks fol-
lowed by 1–2 samples per week thereafter. Acute rejec-
tions were suspected based on plasma creatinine
increase (≥20%), after ruling out other potential causes
such as bacterial infection or drug toxicity etc., and were
verified by renal core biopsies (Banff 97 criteria) [6].
Urine samples from the day of BPAR were compared
with the first available sample after transplantation
(baseline) and from a clinically stable phase, approxi-
mately one week prior to rejection. In the control group
no biopsies were obtained but urine samples from were
attained at similar time points as in the AR-group.
The study was performed in accordance with the Dec-
laration of Helsinki, local laws and regulations, including
the Declaration of Helsinki and Declaration of Istanbul.
The study was reviewed by the regional ethics commit-
tee and signed informed consent, covering also these
urinary proteomics analyses, was obtained before study
start from all patients. The trial EudraCT number is
2005-000219-90 and it is registered on www.clinical-
trials.gov (NCT00139009).
Urine sample preparation
Midstream urine was collected without the addition of
protease inhibitors and allowed to rest at 4°C for up to
one hour, after which it was centrifuged at 800 × g for
10 minutes and stored at −70°C. Sample preparation was
performed as previously described [28,29]. In short, total
protein concentrations was measured using Bradford’s
method [30] and the samples was normalized with re-
spect to this, following cut-off filtration but prior to de-
pletion. A volume of 300 μL was transferred to Vivapure
Anti-HSA kit (Vivascience Sartorius Group) for albumin
depletion. Reduction of the proteins was done using
DTT at 95°C for 15 minutes, followed by alkylation with
iodoacetic acid in the dark at room temperature for
15 min. Tryptic digestion and 18O/16O-labeling of the
samples was done as described earlier [29]. The key
parameters were as follows: A sample volume of 50 μL
was applied to immobilized trypsin beads and digested
using a pH 8.0 buffer at 37°C for 90 minutes under shak-
ing (1200 rpm). Subsequently, the samples were sub-
jected to 18O/16O-labeling using the same beads, but
with a different buffer (pH 6.0) at 37°C for 3 hours
under shaking (1200 rpm). Finally, the samples were
purified and desalted by using in-house produced C18-
tips prior to 2D LC-MS/MS analysis. The AR samples
were labeled with 18O and mixed with both unlabeled
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baseline samples and unlabeled samples from a clinically
stable phase (7–11 days prior to rejection) in the AR-
group. In the control group, the time matched samples
after transplantation was labeled and mixed with un-
labeled baseline samples.
2D LC-MS/MS
Two-dimensional LC-MS/MS was used for separation
and detection of the tryptic digested peptide mixture.
Hydrophilic Interaction Liquid Chromatography (HILIC)
was used as the first dimension of separation and was
done exactly as described previously [28,29]. Fractions
were collected every minute, in total 30 fractions per
sample. All fractions were evaporated on a SpeedVac
(Thermo) and reconstituted in 60 μL of 2% MeCN in
20 mM formic acid. The nanoLC-MS/MS analysis was
done using 20 μL of reconstituted fractions as described
earlier [29] but with a slightly modified HPLC setup:
The reconstituted fractions were trapped on a C18
5 mm x 300 μm id Acclaim PepMap 100 (5 μm) enrich-
ment column (Dionex). The loading mobile phase
20 mM formic acid and MeCN (98/2, v/v) was delivered
at 10 μL/min for 4 minutes. The sample was transferred
to a 150 × 0.075 mm id Acclaim PepMap 100 (pore size
100 Å and particle diameter 3 μm; Dionex) at 300 nL/
min. The mobile phases consisted of A: 20 mM formic
acid and MeCN (95/5, v/v) and B: 20 mM formic acid
and MeCN (5/95, v/v). A linear gradient was run from
0% to 50% B in 60 minutes. Subsequently, the elution
strength was increased to 100%.
The nanospray ionization (NSI) source was operated
in the positive ionization mode (360 μm od× 20 μm id
distal coated fused silica emitter, 10 μm id tip (New Ob-
jective, Woburn, MA, USA). Experiments were per-
formed in two scan events; from m/z 300 to m/z 2000 in
the FT-Orbitrap with resolution R= 30000 and a data
dependent MS/MS with wide band activation carried
out on the highest m/z value. The m/z values fragmen-
ted were dynamically excluded for 15 sec in order to
fragment lower intensity m/z values. Helium gas was
used to cause collision-induced fragmentation at 35%
relative collision energy.
Identification and selection of proteins
The acquired MS data were analyzed and processed
using Proteome Discoverer 1.2 (Thermo) software. The
raw files were analyzed in 2 search nodes, where the first
search node was a SEQUEST™ [31] search against the
FASTA file ipi.HUMAN.v3.76. Carboxymethyl (C) was
set as constant modification while oxidation (M) and
18O (2) on the C-terminal were chosen as variable modi-
fications. The peptide tolerance was set to 10 ppm while
MS/MS tolerance was ±0.8 Da and 2 “missed cleavages”
were allowed using trypsin as enzyme. A decoy database
search was performed by searching against a database
containing the reversed protein sequences with a strict
target false discovery rate (FDR) of 0.01 and a relaxed
FDR of 0.05. Grouping of proteins were enabled and
only the top ranked peptide hits below the FDR thresh-
old (< 0.05) were accepted. The heavy label was set to
18O (2) on the C-terminal, while the light channel con-
tained no modifications. Only unique peptides were used
for quantification and the labeled: unlabeled (18O:16O)
ratios were adjusted against the protein median of all the
quantified proteins in each patient.
Potentially clinically relevant regulation in this proof
of principle study was defined as a fold change of ≥1
(log 2) between baseline and follow-up in at least three
patients in the rejection group but excluding proteins
with significantly higher average ratio in the control
group and proteins more frequently up-regulated in the
control group.
Statistics
The nature of this kind of proof of principle studies
makes relevant statistical analyses difficult. In attempt to
provide a higher statistical power the regulated proteins
were groups by their biological function. For the evalu-
ation of the demographic data and comparison of the
groups, the Mann–Whitney U test was used. A P-value
of <0.05 was considered statistical significant and all
analyses were performed by Minitab version 16.1 (Mini-
tab Inc., Coventry, UK).
Results
Patient demographics
Demographic data of the six patients with acute rejec-
tion and six controls are shown in Table 1. The
patients in the AR-group experienced biopsy proven
acute rejection (BPAR) episodes on average 42 ± 27 days
after transplantation, all C4d negative. No significant
differences were present between the groups with re-
spect to recipient age, HLA mismatch or donor age.
The baseline urine samples were obtained 5.0 ± 3.6 and
4.3±1.8 days after transplantation in the AR- and con-
trol group, respectively.
Up-regulated proteins during AR episodes
A total of eleven proteins showed regulation according to
the predefined criteria (Table 2). Ten of the proteins
belonged to one of two main groups considering their bio-
logical function; proteins involved in regulation of growth
and proteins involved in immune responses. Figure 1 pre-
sents a box plot of the eleven regulated proteins, grouped
by biological function (average of ratios of the different
proteins) and Meprin A subunit alpha (MEP1A), in the re-
jection group and in the controls. At the time of BPAR
the growth factor proteins, as a group, were statistically
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significant up-regulated in the AR-group (P= 0.03). Five of
six patients showed regulation of these proteins above the
predefined threshold. A trend towards up-regulation was
also present for the immune response proteins in the AR-
group (P= 0.13), present in four out of six patients, while
none of the control patients showed regulation. MEP1A
was not detected in any of the control patients but signifi-
cantly up-regulated in all four AR-patients in which the
protein was detected. Figure 2 shows the log 2 changes in
protein levels for the specified protein groups between
baseline and the time of BPAR in the AR-group. The trend
is that these regulated proteins are up-regulated already in
the clinically stable samples, 7–11 days prior to the time
of BPAR.
Discussion
The present analysis identified several up-regulated urin-
ary proteins, but no relevantly down-regulated, in associ-
ation with acute rejection episodes in the early post
transplant phase after kidney transplantation. The results
demonstrate the applicability of combining shotgun pro-
teomics with relative quantification by 18O/16O-labeling
in biomarker discovery using sequential samples from
several patients. This labeling allows determining the
Table 2 Up-regulated proteinsa in AR/control urine samples compared to baseline shown for individual patients
Rejection group No-rejection group
AR 1 AR 2 AR 3 AR 4 AR 5 AR 6 C 1 C 2 C 3 C 4 C 5 C 6
Banff classification I3T1V0
C4d-
I2T2V0
C4d-
I2T2V0
C4d-
I2T2V0
C4d-
I2T3V0
C4d-
I3T1V2
C4d-
NA NA NA NA NA NA
IPI ID Gene ID Protein name Log 2 change Log 2 change
Immune proteins
IPI00217775.1CD74 Isoform 2 of HLA class II histocompatibility
antigen gamma chain
NDb 0.47 2.57 4.06 1.81 1.23 0.39 1.03 0.81 0.99 2.10 0.58
IPI00004573.2PIGR Polymeric immunoglobulin receptor −0.04 0.66 2.27 1.31 0.36 2.20 0.29 0.63 0.71 1.65 0.19 0.14
IPI00783987.2C3 Complement C3 (Fragment) −0.17 3.17 −0.48 1.25 −5.32 2.64 −3.49 ND 1.14 −4.80−1.54−3.63
IPI00017601.1CP Ceruloplasmin 0.42 4.40 0.34 1.15 ND 4.79 −1.87−1.25 0.22 −1.02 0.53 −2.02
IPI00306378.5MASP2 Isoform 2 of Mannan-binding lectin serine
protease 2
1.10 1.88 1.36 2.30 1.26 4.06 0.57 −3.94 1.94 1.19 2.44 0.43
IPI00011302.1CD59 CD59 glycoprotein −2.65 1.16 1.30 1.74 0.40 3.62 −1.52 2.68 −1.90 1.73 1.31 0.19
Growth factors
IPI00016915.1IGFBP7 Insulin-like growth factor-binding protein 7 0.11 −0.43 2.40 1.01 −0.91 2.84 0.71 1.42 0.05 0.58 −0.02 ND
IPI00966866.1EGF Epidermal growth factor 1.71 3.49 2.15 0.75 0.97 ND 0.79 ND ND 1.51 0.51 0.13
IPI00395488.2VASN Vasorin 1.27 1.11 ND 0.61 0.05 2.10 0.96 −2.27 2.00 0.66 1.69 −0.81
IPI00023673.1LGALS3BPGalectin-3-binding protein 1.01 0.20 2.62 1.76 0.61 3.59 0.26 1.21 0.03 1.15 0.32 0.30
Other
IPI00004372.3MEP1A MEP1A protein (Meprin A subunit alpha) ND ND 1.87 2.87 1.31 1.02 ND ND ND ND ND ND
a Criteria for up-regulation: up-regulation (log 2 change ≥1) from baseline to AR in at least three patients in the AR-group. Proteins with higher average ratio in
the control group and proteins more frequently up-regulated in the control group were excluded. b ND: Not detected.
Table 1 Demographic data at time of inclusion
All No-rejection group Rejection group P value
Gender (male/female) 7/5 3/3 4/2
Weight (kg) 75.7 ± 10.2 80.2 ± 11.1 71.3 ± 7.7 0.09
Age (years) 55.0 ± 12.2 59.5 ± 5.4 50.5 ± 15.8 0.26
HLA mismatch (A + B) 1.2 ± 0.9 1.0 ± 1.1 1.3 ± 0.8 0.47
HLA mismatch (DR) 1.2 ± 0.7 1.2 ± 0.8 1.2 ± 0.8 1.00
HLA mismatch (DQ) 0.5 ± 0.5 0.4 ± 0.5 0.5 ± 0.5 0.86
Serum creatininea 143 ± 48 119 ± 55 168 ± 24 0.07
Age donor (years) 51.5 ± 10.8 49.0 ± 14.8 54.0 ± 4.6 0.52
Deceased donor (n) 11/12 6/6 5/6
Data are means ± SD.
aat time of BPAR and matched time-points, respectively.
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relative amount of the proteins identified of two com-
plex samples in one single analysis. Since sample hand-
ling is long, consist of many steps, is laborious and
susceptible to variations, it is a necessity to mix the two
samples early during this procedure. By doing this,
errors caused by variations in individual sample handling
are excluded thus producing a more reliable determin-
ation of the separate protein amounts. By comparing
baseline and event samples in the two groups each pa-
tient serve as its own control. This approach, as com-
pared to the more commonly used pooled sample
strategy, gives a more informative picture since inter-
individual variability can be assessed. Although several
additional validation studies are needed, the proteins
found to be regulated in the present study may be po-
tential biomarkers for acute rejection episodes in renal
transplantation. The up-regulation was detected already
several days prior to the acute rejection was clinically
suspected (increased creatinine). This is an interesting
finding since in addition to being non-invasive the urin-
ary proteome may hence also provide a more sensitive
diagnostic approach for AR. Acute rejection episodes are
a gradual processes and if the altered urine proteome
turns out to be an earlier responding, and more specific,
biomarker of AR it could have dramatic implications on
follow-up of renal transplant recipients and their long-
term outcome. It is plausible that only a minor adjust-
ment of the immunosuppressive therapy is required to
“silence” the activated immune process in an early phase,
and hence avoid full activation.
In the nature of this kind of proof of principle study,
sufficiently powered statistical analyses are difficult to
perform. Looking at the data descriptively, only the
Mannan-binding lectin serin protease 2 (MASP2) was
up-regulated in all patients with AR. The extent of regu-
lation of each protein differed individually as showed in
Table 2, without any obvious pattern. In an attempt to
provide a relevant statistical comparison proteins were
grouped by biological function. This substantiated a po-
tentially relevant regulation in the rejection group also
of the other ten identified proteins. The data may also
indicate a connection between severity of the AR and
the protein regulation as the only patient with arterial
changes (Banff 2 A) showed an almost universally up-
regulation (10 of 11 identified proteins elevated and the
last not detected). The patient who only experienced a
borderline rejection further supports this hypothesis as
only a relatively low degree of regulation was seen (4 of
11 proteins). The possibility to look at regulation pat-
terns of more than one protein is an advantage of the
applied method and can be crucial when looking for bio-
marker candidates.
For the proteins related to immune response, a strong
up-regulation was observed in 4 of the AR-patients. The
two remaining patients, one with only a borderline rejec-
tion actually showed a slight down-regulation. This was
mostly due to a strong down-regulation of acute phase
proteins Complement C3 and CD59 glycoprotein, re-
spectively. In the control group most of the patients
showed decreased levels of immune proteins, especially
for the acute phase proteins.
Earlier studies present data supporting a relevant contri-
bution of many of these proteins in AR episodes. For ex-
ample, the pro-inflammatory cytokine Macrophage
migration inhibitory factor (MIF), the extracellular ligand
for CD74 [32,33], has been associated with AR in kidney
transplants [10]. MASP2, polymeric immunoglobulin re-
ceptor, Ceruloplasmin and participants in the complement
Figure 1 Box plot showing fold change (log2) of immune proteins, growth factors and MEP1A from baseline to acute rejection in the
AR-group compared with the control group.
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system have also been shown to be regulated in associ-
ation with AR [20,34-39].
Cell growth proteins were up-regulated in five of six
patients in the AR-group and are involved in several AR
processes. Insulin-like growth factor-binding protein 7
(IGFBP7) modulate effects of vascular endothelial growth
factor (VEGF) [40] and is reported to interact with Che-
mokines in venous endothelium including IFN-γ-inducible
protein 10 (IP-10; CXCL10) [41,42], which has previ-
ously been reported to be elevated in urine in connec-
tion with AR [13,17]. Vasorin and Galectin-3-binding
protein are closely associated to transforming growth
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factor-beta (TGF-β1) and IL-6, both linked to acute re-
jection in this population [15,43-48].
MEP1A protein does not fit to either of the two pro-
tein groups and was only detected in the AR-group, sig-
nificantly up-regulated at the time of AR. The absence
of identified MEP1A in the control group is an interest-
ing observation and could potentially be very useful in a
diagnostic setting. It should however be kept in mind
that this is only a proof of principle study so a wide
range of further validation series have to be performed
to ensure that the observations are clinically relevant.
Many urinary proteins that previously have been
shown to be regulated in association with AR were also
detected in our study, but not regulated enough to fulfill
the predefined criteria [20] [49]. In addition, other pro-
teins have been investigated using a more targeted ap-
proach (e.g. ELISA) but these were not confirmed by our
investigation [10-19,21].
In addition to looking at the whole proteome a major
strength of our analysis is that each patient was his or her
own control, comparing the protein levels at baseline with
sequential follow-up time points, in a well defined patient
population. This allowed us to show that the proteins were
regulated already several days before clinical suspicion of
AR. In addition, individual samples were analyzed in the
present study, not pooled urine, providing more detailed
information of the regulation in association with the AR.
The current study lack however a post treatment sample
in order to be perfectly complete. With such a sample it
would have proven that the regulation was specific to acute
rejection episodes. Unfortunately such samples were not
collected. Another indication of the relevance of the
current findings is that all identified proteins are physio-
logical plausible to be involved in an acute rejection epi-
sode. The major limitation of this proof of principle study
is the relative limited small sample-size compared to clas-
sical approaches. This, however, has its cause in the time
consuming and labor intensive nature of the full shotgun
proteomic approach chosen. Even though it is applicable
for first identification of potential biomarkers, analysis of
each digested sample took almost one week to finalize.
Somewhat overlap in analysis is possible but in general it is
a too labor demanding procedure for large studies. In fu-
ture validation of the present findings a more targeted ana-
lytical approach has to be utilized. It should also be
pointed out that the control group patients were not veri-
fied non-rejectors by protocol biopsies. Previous studies
have shown an incidence of almost 30% subclinical rejec-
tions in apparently stable patients on CsA based immuno-
suppression [50,51]. It is hence possible that sub-clinical
rejections could be present in some of the controls, making
the interpretation somewhat biased. Further prospective
studies are needed in larger populations, where biopsies
also are performed in the controls, to fully elucidate on the
involvement of these proteins in AR and their potential us-
ability as diagnostic biomarkers.
Conclusion
This study shows the applicability of shotgun proteomics
in combination with relative quantification by 18O/16O-
labeling in biomarker discovery in sequential urine sam-
ples. Two groups of physiological related proteins with
relevance to immunological processes during AR epi-
sodes were found to be up-regulated in patients with
BPAR.
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